Drug Trial Radar · NCT05103332
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2)
Last checked: Nov 20, 2026Latest source record: Nov 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
663
Actual
Start
Nov 5, 2021
Primary completion
Dec 11, 2023
Study completion Sep 13, 2024
Sponsor
- Lead sponsor
- Alnylam PharmaceuticalsAlnylam Pharmaceuticals (ALNY)
- Sponsor type
- Industry
- First posted
- Nov 2, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the effect of zilebesiran on systolic and diastolic blood pressure and to characterize the pharmacodynamic (PD) effects and safety of zilebesiran as add-on therapy.
Conditions
- Hypertension
Interventions
IndapamideDrug
Indapamide administered orally
AmlodipineDrug
Amlodipine administered orally
OlmesartanDrug
Olmesartan administered orally
PlaceboDrug
Placebo administered by SC injection
ZilebesiranDrug
Zilebesiran administered by SC injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Indapamide: Change From Baseline at Month 3 in 24-hour Mean SBP Assessed by ABPM - Censored DataTime frame: Baseline and Month 3
- Amlodipine: Change From Baseline at Month 3 in 24-hour Mean SBP Assessed by ABPM - Censored DataTime frame: Baseline and Month 3
- Olmesartan: Change From Baseline at Month 3 in 24-hour Mean SBP Assessed by ABPM - Censored DataTime frame: Baseline and Month 3
Locations
110 sites in 8 countries. Site status is shown where the registry gives one.
Clinical Trial Site
Mesa, Arizona
Clinical Trial Site
Tempe, Arizona
Clinical Trial Site
Tempe, Arizona
Clinical Trial Site
Bell Gardens, California
Clinical Trials Site
Beverly Hills, California
Clinical Trial Site
Canoga Park, California
Clinical Trial Site
Carlsbad, California
Clinical Trial Site
Encinitas, California
Clinical Trial Site
Garden Grove, California
Clinical Trial Site
Hollywood, California
Clinical Trial Site
Huntington Beach, California
Clinical Trial Site
Irvine, California
Clinical Trial Site
Long Beach, California
Clinical Trial Site
Los Angeles, California
Clinical Trial Site
Mission Hills, California
Clinical Trial Site
Oceanside, California
Clinical Trial Site
Panorama City, California
Clinical Trial Site
San Diego, California
Clinical Trial Site
Santa Clarita, California
Clinical Trial Site
South Gate, California
Clinical Trial Site
Tustin, California
Clinical Trial Site
Upland, California
Clinical Trial Site
Washington D.C., District of Columbia
Clinical Trial Site
Clearwater, Florida
Clinical Trial Site
Coconut Creek, Florida
Clinical Trial Site
Coral Gables, Florida
Clinical Trial Site
Hollywood, Florida
Clinical Trial Site
Hollywood, Florida
Clinical Trial Site
Inverness, Florida
Clinical Trial Site
Jacksonville, Florida
Clinical Trial Site
Miami, Florida
Clinical Trial Site
Miami, Florida
Clinical Trial Site
Miami, Florida
Clinical Trial Site
Miami, Florida
Clinical Trial Site
Miami, Florida
Clinical Trial Site
Naples, Florida
Clinical Trial Site
Orlando, Florida
Clinical Trial Site
Orlando, Florida
Clinical Trial Site
Pembroke Pines, Florida
Clinical Trial Site
Tampa, Florida
Showing 40 of 110 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.